Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 8c, Revenues Miss; Offers FY19 Revenue Outlook

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.01), $0.08 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $47.71 million versus the consensus estimate of $51.74 million.

"During the first quarter, Vanda made significant advances towards its commercial and research goals. Patients on treatment with Hetlioz continue to increase steadily, driven by broader awareness and recognition of Non-24. We are preparing for a possible launch later this year in jet lag disorder, an indication that has the potential to drive significant growth for our Hetlioz franchise. Tradipitant clinical development is advancing for three indications, atopic dermatitis, gastroparesis and motion sickness," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "We believe that Vanda is well positioned for significant growth in the coming quarters and years given its strong commercial and clinical development pipeline and its exceptional people."

Key Financial Highlights:

• Total net product sales from HETLIOZ® and Fanapt® were $47.7 million in the first quarter of 2019, a 10% decrease compared to $53.0 million in the fourth quarter of 2018 and a 9% increase compared to $43.6 million in the first quarter of 2018.
• HETLIOZ® net product sales were $29.0 million in the first quarter of 2019, an 11% decrease compared to $32.4 million in the fourth quarter of 2018 and a 14% increase compared to $25.4 million in the first quarter of 2018. In the first quarter of 2019, HETLIOZ® units sold to patients declined by 2% compared to the fourth quarter of 2018.
• Fanapt® net product sales were $18.8 million in the first quarter of 2019, a 9% decrease compared to $20.6 million in the fourth quarter of 2018 and a 3% increase compared to $18.2 million in the first quarter of 2018. In the first quarter of 2019, Fanapt® prescriptions, as reported by IQVIA, declined by 5% compared to the fourth quarter of 2018.
• Cash, cash equivalents and marketable securities (Cash) were $267.8 million as of March 31, 2019, representing an increase to Cash of $10.5 million and $19.0 million as compared to December 31, 2018 and March 31, 2018, respectively.

GUIDANCE:

Vanda Pharmaceuticals sees FY2019 revenue of $215-225 million, versus the consensus of $221.36 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• FTI Consulting names Jerome Nyssen senior managing director in Australia
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings